Charlotte B Wagner
A5082532520- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Acute Myeloid Leukemia Research
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Hematopoietic Stem Cell Transplantation
- Safe Handling of Antineoplastic Drugs
- Neutropenia and Cancer Infections
- Viral-associated cancers and disorders
- Monoclonal and Polyclonal Antibodies Research
- Viral Infectious Diseases and Gene Expression in Insects
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Mast cells and histamine
- Peptidase Inhibition and Analysis
- Blood disorders and treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Quinazolinone synthesis and applications
- Polyomavirus and related diseases
- Histone Deacetylase Inhibitors Research
- Oral health in cancer treatment
Huntsman Cancer Institute
2021-2025
University of Utah
2021-2025
University of Utah Hospital
2024
Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of phase II pivotal KarMMa trial, which demonstrated best overall and ≥ complete response rates 73% 33%, respectively. We report clinical outcomes with standard-of-care (SOC) ide-cel under commercial Food Drug Administration label.
Abstract Most patients with multiple myeloma experience disease relapse after treatment a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for treated sequential BCMA-TT are limited. We analyzed clinical infused standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 prior exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) 153 no were ide-cel, median follow-up...
While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted CAR T-cell therapy. Understanding the characteristics these is important patient selection development novel strategies to improve outcomes. We evaluated factors associated with progression (progression death due myeloma ≤ 3 months T infusion) in treated standard care ide-cel at...
PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, survival among patients with RRMM treated standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of leukapheresed by December 31, 2022, the intent to receive SOC...
Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain US Food and Drug Administration approval for patients with relapsed/refractory multiple myeloma (RRMM). The clinical outcomes of standard care (SOC) ide-cel in racially ethnically diverse populations have been understudied. This study pooled data from 207 RRMM (28% racial ethnic minority groups) treated SOC across 11 institutions examine differences incidence toxicities adverse events, response...
Introduction Horse antithymocyte globulin carries a black box warning for life-threatening anaphylactic reactions, and prescribing information recommends test doses to identify patients at highest risk of this adverse effect. The predictive value such is not well validated, practicality use unclear. Methods This was planned secondary analysis multicenter, retrospective cohort study in adults with severe aplastic anemia being managed horse as part their treatment regimen. Qualitative...
Abstract Brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is increasingly used for frontline treatment of stage III/IV classical Hodgkin lymphoma (cHL). Peripheral neuropathy (PN) was the most common treatment-limiting side effect seen clinical trials but has not been studied a nontrial setting, which clinicians may have different strategies managing it. We conducted multisite retrospective study to characterize PN patients who received BV + AVD...
Sixteen cycles of Brentuximab vedotin (BV) after autologous stem cell transplant (ASCT) in high-risk relapsed/refractory classical Hodgkin lymphoma demonstrated an improved 2-year progression-free survival (PFS) over placebo. However, most patients are unable to complete all 16 at full dose due toxicity. This retrospective, multicenter study investigated the effect cumulative maintenance BV on PFS. Data were collected from who received least one cycle ASCT with following features: primary...
8013 Background: Ide-cel is an FDA-approved treatment for RRMM patients (pts). However, there limited data on how BT disease control during its manufacturing process affects clinical outcomes. Methods: Eleven US academic centers contributed to this analysis without involvement from the manufacturer. By 5/1/2022, 235 pts had undergone leukapheresis, with 214 infused a median follow up of 9 months (mos). was given between leukapheresis and CAR-T infusion. Results: In analysis, 79% (n = 170)...
OBJECTIVES Neonatal seizures are common complications. Phenobarbital is the agent of choice but leads to adverse neurologic outcomes. There has been increased use newer agents like levetiracetam. The objective this study was determining rate seizure resolution in neonates treated with phenobarbital or METHODS This a retrospective, single-center, cohort from June 1, 2012–June 2018 evaluating following first-line treatment versus Data were collected via review patient's charts electronic...
Idecabtagene vicleucel (ide-cel) has shown impressive efficacy in relapsed-refractory multiple myeloma (RRMM). The aim of this study was to investigate the impact absolute lymphocyte count (ALC) on survival outcomes RRMM patients treated with standard care (SOC) ide-cel. Data were retrospectively collected from 11 institutions U.S. Impact ALC parameters including pre-apheresis (pre-A), pre-lymphodepletion (pre-LD), and percent difference pre-A pre-LD clinical after ide-cel examined using...